Podoplanin is a novel antibody-based therapeutic target for glioblastoma
Publication
, Journal Article
Kato, Y; Mishima, K; Kaneko, M; Zalutsky, M; Kuan, C-T; Bigner, D
Published in: CANCER RESEARCH
2009
Duke Scholars
Published In
CANCER RESEARCH
EISSN
1538-7445
ISSN
0008-5472
Publication Date
2009
Volume
69
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Kato, Y., Mishima, K., Kaneko, M., Zalutsky, M., Kuan, C.-T., & Bigner, D. (2009). Podoplanin is a novel antibody-based therapeutic target for glioblastoma. CANCER RESEARCH, 69.
Kato, Yukinari, Kazuhiko Mishima, Mika Kaneko, Michael Zalutsky, Chien-Tsun Kuan, and Darell Bigner. “Podoplanin is a novel antibody-based therapeutic target for glioblastoma.” CANCER RESEARCH 69 (2009).
Kato Y, Mishima K, Kaneko M, Zalutsky M, Kuan C-T, Bigner D. Podoplanin is a novel antibody-based therapeutic target for glioblastoma. CANCER RESEARCH. 2009;69.
Kato, Yukinari, et al. “Podoplanin is a novel antibody-based therapeutic target for glioblastoma.” CANCER RESEARCH, vol. 69, 2009.
Kato Y, Mishima K, Kaneko M, Zalutsky M, Kuan C-T, Bigner D. Podoplanin is a novel antibody-based therapeutic target for glioblastoma. CANCER RESEARCH. 2009;69.
Published In
CANCER RESEARCH
EISSN
1538-7445
ISSN
0008-5472
Publication Date
2009
Volume
69
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis